Lonza Upgrades Clinical Manufacturing Services at Bend (US) Site to Include Bottling & Labeling Capabilities
Lonza, a global partner to the pharmaceutical, biotech, and nutraceutical markets, recently announced the addition of clinical bottling and labeling capabilities at its Small Molecules site in Bend, OR (US). Building upon the recent investment in the dedicated early phase clinical manufacturing facility, the offering now includes new bottling equipment for filling tablets and powder-filled capsules. The additional equipment will further support customers in the early stages of development.
The new equipment can detect defects in tablets and capsules as well as clean, fill, cap and seal, and label bottles intended for use in early-phase clinical trials. This enables Lonza to speed up product delivery to clinical trial centers, which is crucial in its customers’ journey toward clinical trials.
Matthew Ferguson, Senior Director, Product Development, Small Molecules, Lonza, said “Lonza’s Drug Product Formulation and Development Services, offered from our site in Bend (US), supports clinical and commercial development and manufacturing. The new bottling equipment for filling tablets and powder-filled capsules further enhances our ability to support customers looking to accelerate their candidate pathway through phase I and II clinical trials and beyond.”
Lonza’s facility in Bend serves as the company’s Center of Excellence for bioavailability enhancement and inhaled delivery. For more than 45 years, the Bend team has been at the forefront of addressing solubility challenges and modulating pharmacokinetics to meet target product profiles. The site currently supports more than 80 programs.
To learn more about Lonza’s upgraded clinical manufacturing services, visit Clinical Packaging, Labelling and Supply Services | Lonza.
Total Page Views: 405
